FiercePharma1h
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...
FiercePharma6h
EU drug reviewers back Novo Nordisk’s FDA-rejected hemophilia drug, snub PTC’s Translarna again
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
FiercePharma6h
Lilly joins OAC campaign against obesity stigma, partnering on gallery of bias-free images for use in media coverage
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
FiercePharma7h
Baxter to import 18,000 tons of IV product by year-end as hurricane recovery efforts continue in NC
As recovery efforts at the North Carolina plant hit by Hurricane Helene move at an “encouraging pace,” Baxter International ...
FiercePharma7h
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...
FiercePharma7h
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
FiercePharma9h
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...